Highlights

  • Artrya (ASX:AYA) is commercialising its Salix coronary imaging platform.
  • Huntsville signed a five-year commercial agreement in October 2026.
  • The Huntsville contract carries a minimum value of USD 0.5 million.
  • US hospital deployment and product utilisation remain key monitoring points.

Artrya Limited develops artificial intelligence-enabled software for assessing coronary artery disease using cardiac computed tomography imaging. Shares in Artrya (ASX:AYA) traded at AUD 3.07 on 16 November 2026, down 3.76% during the session. Its recent corporate announcements have focused on converting US hospital relationships into commercial use of the Salix platform and extending the system’s role in clinical workflows.

Salix Platform and Clinical Workflow

Artrya (ASX:AYA) is commercialising the cloud-based Salix platform, which supports assessment of coronary computed tomography angiography (CCTA) scans. Salix Coronary Anatomy forms part of the commercial offering, alongside the Coronary Plaque module. Coronary Flow remains subject to applicable regulatory requirements before commercial deployment where clearance is required.

The Business model involves hospital contracts, software subscriptions and, for relevant products, scan-based charges. It therefore depends not only on securing agreements but also on installing software, integrating with hospital technology and achieving routine clinician use. US activity is a central part of Artrya’s current commercial strategy.

Huntsville Agreement and September Quarter

In October 2026, Artrya (ASX:AYA) announced a five-year commercial agreement with Huntsville Hospital Health System, its largest customer at that point. The agreement was disclosed with a minimum contracted value of USD 0.5 million for Salix Coronary Anatomy. Huntsville also became the first participant in the SAPPHIRE study to convert to a full commercial arrangement.

The agreement covers subscription use of the anatomy product, while additional scan-based charges may apply to other modules under the stated commercial terms and relevant clearances. Artrya explained that deploying its technology involves integration with image archiving systems, hospital IT, clinical workflows and relevant reimbursement processes. A contracted minimum should not be confused with Revenue already recognised.

Its September-quarter activities update also described increased use of Salix Coronary Plaque at Tanner Health after introduction of a pre-authorisation workflow. The observation concerned utilisation at a customer site, rather than a company-wide measure of recurring software revenue.

Financial Position and Commercial Context

Artrya reported a loss attributable to owners of AUD 25.183 million for FY26, as disclosed in its annual reporting. The company remains in a commercial-building phase in which sales contracts, system implementations and scan volumes may develop at different rates. The significance of announced contracts needs to be evaluated alongside subsequent receipts and the cost of expanding US operations.

In its September-quarter report, Artrya (ASX:AYA) identified conversion of customers to regular Salix use as a priority. Adoption of coronary imaging software also depends on clinical evidence, institutional purchasing processes, approval pathways and integration into established medical workflows. A hospital agreement alone does not establish future scanning volumes or profitability.

The company has identified the conversion of existing deployments into regular clinical use as an important operational measure. The number of contracted hospitals and the number actively processing scans are different indicators. Reporting on recurring subscription income, incremental plaque-related usage and timing of implementation will therefore provide a clearer comparison of operational progress over successive quarters, without assuming that all contracted fees have been collected.

Risks to Consider

Key risks for Artrya (ASX:AYA) include implementation delays, uncertain per-site utilisation, extended hospital procurement cycles and the expense of supporting US installations. Regulatory processes for additional modules may affect the available product range. Recurring Revenue can also differ materially from headline contracted values as installation schedules and customer usage change.

What to Watch Next

Future reports may clarify the timing of Huntsville installation and activation, use of Salix at existing hospital customers and subsequent subscriptions or scan-based revenue. Investors may monitor new SAPPHIRE participant conversions, the progress of regulatory submissions and changes in operating cash requirements as the commercial footprint expands.

Key Insights

Artrya (ASX:AYA) has moved part of its US hospital network from research participation toward contracted commercial use. The next measure of execution will be evidence of deployed sites, scan utilisation and revenue recognition rather than contract announcements alone.